Varicella vaccines

Current Opinion in Infectious Diseases

Volumn 25, Issue 2, 2012, Pages 135-140

  Javed, Saba ^a   Javed, Syed A ^b   Tyring, Stephen K ^c  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b TEXAS A M COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

herpes zoster; postherpetic neuralgia; varicella; varivax; zostavax

Indexed keywords

CHICKENPOX VACCINE; VARICELLA ZOSTER VACCINE;

DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HERPES ZOSTER; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; NONHUMAN; POSTHERPETIC NEURALGIA; REVIEW; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; VARICELLA ZOSTER VIRUS; VIRUS LOAD;

CHICKENPOX VACCINE; HERPES ZOSTER; HERPESVIRIDAE INFECTIONS; HUMANS; IMMUNOCOMPETENCE; NEURALGIA, POSTHERPETIC;

EID: 84858005824     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32834c1863     Document Type: Review

References (26)

1. Lopez AS, Zhang J, Brown C, Bialek S. Varicella-related hospitalizations in the United States, 2000-2006: the 1-dose varicella vaccination era. Pediatrics 2011; 127:238-245.
2. Smith PJ, Singleton JA. County-level trends in vaccination coverage among children aged 19-35 months: United States, 1995-2008. MMWR Surveill Summ 2011; 60:1-86.
3. National, state, and local area vaccination coverage among adolescents aged 13-17 years: United States, 2009. MMWR Morb Mortal Wkly Rep 2010; 59:1018-1023.
4. National, state, and local area vaccination coverage among children aged 19-35 months: United States, 2009. MMWR Morb Mortal Wkly Rep 2010; 59:1171-1177.
5. Sauerbrei A, Stefanski J, Gruhn B, Wutzler P. Immune response of varicella vaccinees to different varicella-zoster virus genotypes. Vaccine 2011; 29:3873-3877. This study provides the first experimental evidence that the Oka strain vaccine induces antibody response directed against the VZV circulating in Germany.
6. Spackova M, Wiese-Posselt M, Dehnert M, et al. Comparative varicella vaccine effectiveness during outbreaks in day-care centres. Vaccine 2010; 28:686-691. This study compares the efficacy of three varicella vaccines in Germany: Varivax, Varilrix, and Priorix-Tetra.
7. Shapiro ED, Vazquez M, Esposito D, et al. Effectiveness of 2 doses of varicella vaccine in children. J Infect Dis 2011; 203:312-315. This study confirms that two doses of varicella vaccine are much more effective then one dose in preventing varicella.
8. Kattan JA, Sosa LE, Bohnwagner HD, Hadler JL. Impact of 2-dose vaccination on varicella epidemiology: Connecticut: 2005-2008. J Infect Dis 2011; 203:509-512.
9. Han JY, Hanson DC, Way SS. Herpes zoster and meningitis due to reactivation of varicella vaccine virus in an immunocompetent child. Pediatr Infect Dis J 2011; 30:266-268. Authors describe a previously immunized, immunocompetent child who developed herpes zoster with meningitis after reactivation of vaccine strain of VZV.
10. Klein NP, Fireman B, Yih WK, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics 2010; 126:e1-e8.
11. Marin M, Broder KR, Temte JL, et al. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:1-12.
12. Cheuk DK, Chiang AK, Lee TL, et al. Vaccines for prophylaxis of viral infections in patients with hematological malignancies. Cochrane Database Syst Rev 2011; CD006505.
13. Chou JF, Kernan NA, Prockop S, et al. Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT). Biol Blood Marrow Transplant 2011 [Epub ahead of print]. Authors assess patients with hematological malignancies who received varicella vaccine and conclude that vaccine might reduce the incidence of herpes zoster.
14. Lu Y, Bousvaros A. Varicella vaccination in children with inflammatory bowel disease receiving immunosuppressive therapy. J Pediatr Gastroenterol Nutr 2010; 50:562-565. This study presents a good immune response to the varicella vaccine in children with inflammatory bowel disease receiving immunosuppressive therapy.
15. Taweesith W, Puthanakit T, Kowitdamrong E, et al. The immunogenicity and safety of live attenuated varicella-zoster virus vaccine in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2011; 30:320-324. Administration of two doses of varicella vaccine in HIV-infected children resulted in high seroconversion rates.
16. Son M, Shapiro ED, LaRussa P, et al. Effectiveness of varicella vaccine in children infected with HIV. J Infect Dis 2010; 201:1806-1810.
17. Gershon AA, Levin MJ, Weinberg A, et al. A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella. Pediatr Infect Dis J 2009; 28:653-655.
18. Weinberg A, Levin MJ, Macgregor RR. Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults. Hum Vaccin 2010; 6:318-321. Administration of varicella vaccine in HIV-infected adults resulted in a modest immune response.
19. Schneider L, Weinberg A, Boguniewicz M, et al. Immune response to varicella vaccine in children with atopic dermatitis compared with nonatopic controls. J Allergy Clin Immunol 2010; 126:1306-1307; e1302.
20. Pileggi GS, de Souza CB, Ferriani VP. Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. Arthritis Care Res (Hoboken) 2010; 62:1034-1039. Excellent immunogenicity from a single dose of varicella vaccine in patients with juvenile rheumatic diseases.
21. Hicks LD, Cook-Norris RH, Mendoza N, et al. Family history as a risk factor for herpes zoster: a case-control study. Arch Dermatol 2008; 144:603-608. (Pubitemid 351724420)
22. Lu PJ, Euler GL, Harpaz R. Herpes zoster vaccination among adults aged 60 years and older, in the U.S., 2008. Am J Prev Med 2011; 40:e1-e6.
23. OxmanMN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-2284.
24. Simberkoff MS, Arbeit RD, Johnson GR, et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med 2010; 152:545-554.
25. MacIntyre CR, Egerton T, McCaughey M, et al. Concomitant administration of zoster and pneumococcal vaccines in adults >/=60 years old. Hum Vaccin 2010; 6:894-902.
26. Mills R, Tyring SK, Levin MJ, et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine 2010; 28:4204-4209. Immunogenicity of zoster vaccine in adults who had a prior episode of herpes zoster